Neurocrine Biosciences, Inc..
NBIX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio includes FDA-approved products for tardive dyskinesia, endometriosis, uterine fibroids, and Parkinson's dis...Show More
Better Health for All
30
Neurocrine Biosciences' core business is entirely focused on developing and commercializing treatments for neurological, endocrine, and psychiatric disorders, including FDA-approved products for tardive dyskinesia, endometriosis, uterine fibroids, Parkinson's disease, genetic disorders, and movement disorders.
1
Its pipeline includes drug candidates for dyskinetic cerebral palsy, major depressive disorder, schizophrenia, movement disorders, epilepsy, and congenital adrenal hyperplasia.
2
All products and pipeline candidates are designed to provide health benefits, with no evidence of products causing negative health consequences. The company's focus on psychiatric disorders and conditions like major depressive disorder and schizophrenia directly addresses mental health needs.
Fair Money & Economic Opportunity
0
No evidence available to assess Neurocrine Biosciences, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
Neurocrine Biosciences reported a CEO pay ratio of 35:1 for 2024, based on CEO Kyle W. Gano's pay of $9,235,299 and a median employee pay of $265,089.
1
The company's employee engagement score was 98% in 2020, consistently surpassing the 90th percentile in industry benchmarks for employee experience within the biotech sector.
2
An annual employee survey achieved a 92% response rate, and 80% of employees would recommend the company to a friend.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Neurocrine Biosciences, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-30
Neurocrine Biosciences has a comprehensive whistleblower policy, including a 24/7 anonymous ethics hotline managed by a third-party vendor, and explicitly prohibits retaliation for good faith reports.
1
While annual training is required for the related Anti-Bribery and Corruption Policy
2
and employees certify adherence to the Code of Ethics,
3
the effectiveness of the whistleblower program is not publicly measured. The company has not reported any financial restatements in its 2025 Corporate Responsibility Report, indicating no formal restatements.
4
Neurocrine conducts routine internal and external audits related to GCP, GLP, and GMP regulations, and performs biannual product safety audits on every GMP manufacturer, but the overall percentage of revenue or assets covered by independent external audit is not explicitly stated.
5
The board's policy mandates a majority of independent directors, and only independent directors serve on the Audit, Compensation, and Nominating/Corporate Governance Committees, but a specific percentage of conflict-free board members is not provided.
6
The company has a comprehensive Anti-Bribery and Corruption Policy that applies to all employees, officers, and directors, as well as anyone doing business on its behalf, with required annual training, but it lacks customization for high-risk areas.
7
While the ethics hotline is managed by a third-party
8
and thorough background checks are run on intermediaries,
9
the extent of independent verification of ethical claims is not broadly detailed beyond these specific instances.
Kind to Animals
0
No evidence available to assess Neurocrine Biosciences, Inc. on Kind to Animals.
No War, No Weapons
0
Neurocrine Biosciences is a biopharmaceutical company. The provided articles indicate no involvement in arms manufacturing, military contracts, or dual-use technology with military applications, leading to a score of 0 for most related KPIs. The company has a comprehensive compliance program and a Supplier Code of Conduct, requiring employees to annually certify compliance to the Code of Business and Ethics.
1
It also conducts an annual supply chain end-to-end risk assessment and requires suppliers to adhere to laws relating to conflict minerals, though no specific percentage of conflict-free materials is provided.
2
There is no evidence of sales to embargoed regimes, peacebuilding investments, or specific ethical red lines related to weapons.
Planet-Friendly Business
0
No specific quantitative data or verifiable actions related to environmental performance, targets, or compliance were found in the provided articles for Neurocrine Biosciences, Inc.
1
The summaries indicate a lack of available hardcopy reports and specific metrics for analysis, including emissions, renewable energy use, water consumption, waste diversion, or climate-related initiatives.
2
There is also no information on regulatory actions, violations, fines, or certifications.
3
Respect for Cultures & Communities
0
The provided articles discuss Neurocrine Biosciences, Inc.'s internal compliance program, general diversity and inclusion initiatives, and sponsorships of broader community events such as a science festival and a mental health walk. However, no specific, quantitative evidence was found regarding formal partnerships with indigenous or local community groups, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, community grievance mechanisms, FPIC participation, community governance inclusion, cultural preservation investment, local or indigenous procurement, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.
Safe & Smart Tech
0
Neurocrine Biosciences participates in and complies with the EU-U.S. Data Privacy Framework, its UK Extension, and the Swiss-U.S. Data Privacy Framework.
1
The company's privacy policy allows users to opt-out of marketing communications and request access, correction, or deletion of their personal data.
2
The company states that data is retained only as long as necessary for its purpose.
3
Neurocrine Biosciences explicitly states compliance with various regulations, including CCPA, European data protection laws, FDA, EMA, ICH, and GCP, and has a comprehensive compliance program.
4
All employees are required to read, be trained, and annually certify compliance to the Code of Business and Ethics.
5
No documented incidents of unauthorized data use were found.
Zero Waste & Sustainable Products
-30
Neurocrine Biosciences achieved a hazardous waste recycling rate of 99.6% in 2024, recycling 102,760 lbs and not recycling 359 lbs, utilizing EPA-aligned methods such as solvent recovery and fuel blending.
1
The company has consistently exceeded its goal of maintaining over 90% hazardous waste recycling.
2
Its 2nd Generation manufacturing process for INGREZZA has reduced total waste by 53% and increased product yield by 5%, eliminating over 200 metric tons of waste for every metric ton manufactured.
3
Neurocrine applies Green Chemistry and Engineering principles across its portfolio and is a leading member of the American Chemical Society Green Chemistry Institute’s Pharmaceutical Roundtable.
4
Facilities are subject to annual program-specific and other periodic internal and external environment, health, and safety (EHS) audits.
5
The company has had no waste disposal violations in the past three years.
6
Suppliers are encouraged to conserve natural resources and avoid hazardous materials, and Neurocrine assesses suppliers' corporate responsibility efforts annually, considering EcoVadis rankings.
7